Clinical Trial Update: PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease [Phase 2]

View source ↗

Summary

A Phase 2 dose-response study (PLASMA Trial) of A-002 in subjects with stable coronary artery disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• A-002

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Coronary Artery Disease (CAD) | Phase 2 | Status: COMPLETED